Copy to clipboard 
Premia Spine announced the publication of clinical data demonstrating that its TOPS System provides significant health system and societal benefits vs. transforaminal lumbar interbody fusion (TLIF). Reported to be the first and only facet joint replacement system for the lumbar spine, TOPS was developed to provide lasting mobility, stability and durability after decompression for patients with lumbar spinal stenosis and degenerative spondylolisthesis.
Published in the Journal of Health Economics and Outcomes Research, “A Prospective Study of Lumbar Facet Arthroscopy in the Treatment of Degenerative Spondylolisthesis and Stenosis: Early Cost-Effective Assessment from the Total Posterior Spine System (TOPS) IDE Study,” the study explored the cost-effectiveness and economic analysis of the TOPS System versus TLIF for patients with spondylolisthesis and spinal stenosis. Patients were randomly assigned to either TOPS or TLIF surgery as part of a prospective, multi-center U.S. clinical trial.
Premia Spine’s TOPS System is the reported first and only facet joint replacement system for the lumbar spine. It was developed to help patients with lumbar spinal stenosis and degenerative spondylolisthesis. Photo courtesy of Premia Spine.
The data from the study was analyzed by Neuronomics, an independent professional corporation focusing on healthcare economic analyses. Its findings demonstrate that, even at a premium of $4,000 over the cost of a TLIF implant, TOPS still achieves cost-effectiveness at a willingness-to-pay threshold of $100,000 within one year after surgery. Furthermore, TOPS becomes the dominant strategy when data is examined at two years and beyond. From the societal perspective, TOPS is even more highly cost-effective at one year and dominant at two years and beyond.
TOPS has been given Breakthrough Device Designation from FDA and is currently the subject of a pivotal clinical trial under an investigational device exemption from FDA.
“We developed TOPS to address a significant unmet need in the treatment of spinal stenosis and spondylolisthesis, and this study data demonstrate that TOPS not only provides clinical benefit to patients but also cuts sizeable treatment costs to hospital providers and payers,” Ron Sacher, CEO, Premia Spine, said. “TOPS is well poised to be a win-win for patients, surgeons, facilities, and payers.”
